The Trump administration has launched a “War on Fraud” and taken a series of decisive steps to crack down on healthcare fraud. Most prominently, the administration is threatening to punish the state of Minnesota by withholding up to $3 billion in annual funding, while signaling that additional enforcement in other states is forthcoming. Capstone believes the administration’s crackdown is just getting started.
We sat down with Capstone Healthcare analyst Will Humphrey to discuss the extent of the crackdown and how it will impact state Medicaid budgets, provider groups, hospital systems, and insurers.
Q: Will, what are the biggest risks to investors?
A: Our base case is that the administration’s fraud crackdown is primarily a messaging strategy – politically favorable enforcement actions that generate headlines without fundamentally disrupting Medicaid funding. The risk is that it escalates beyond that, and that the administration, in its effort to reclaim the narrative on healthcare affordability ahead of the midterms, deploys the full breadth of its enforcement toolbox to punish states with real or perceived fraud, rather than working collaboratively with state governments to address these issues.
In Minnesota, for example, there has been well-documented fraudulent activity that the state has worked hard to address. However, CMS’ initiation of never-before-used noncompliance proceedings represents a new phase in federal efforts to rein in improper spending – in my view, it amounts to using a sledgehammer where a scalpel is needed. Through this authority, the administration is threatening to withhold approximately $2 billion in federal Medicaid funding per year. It has since doubled down, announcing the deferral of $260 million in federal Medicaid funding every quarter unless Minnesota can prove that certain payments are legitimate.
For investors, the primary risk is that these funds are actually withheld and the resulting budget shortfall forces the state to take drastic cost-containment actions – potentially including cuts to rates paid to providers. This would be most disruptive for providers that rely heavily on Medicaid reimbursement, such as those in Personal Care Services (PCS), Intellectual and Developmental Disabilities (IDD), and Home and Community Based Services (HCBS), but the impact would extend to hospital systems as well.
Investors with exposure to Medicaid Managed Care Organizations (MCOs) such as Centene Corp. (CNC) and Molina Healthcare Inc. (MOH) should also be monitoring these proceedings. If states resort to cost-containment measures, capitated rates paid to MCOs could be on the table for cuts as well.
We are in the early innings, but I believe rate cuts are unlikely at this point. I expect CMS will not ultimately withhold the full amounts threatened – either because Minnesota successfully appeals the decision, or because the state’s vigorous corrective actions provide political cover for the administration to claim a “win” and walk back the most severe penalties. Minnesota also maintains a robust rainy-day fund and has recently demonstrated a willingness to tap it to cover federal funding shortfalls. The outlook in other states is less certain, and will depend largely on which enforcement tools the administration chooses to deploy.
We will be watching to see whether CMS applies a similar playbook in other target states, such as California, Massachusetts, and Maine, or opts for less punitive measures and works with states to more precisely root out bad actors. We’re also monitoring whether the administration expands its crackdown to Medicare fraud, which could carry additional implications for hospice and home health providers.
Q: What are second-order effects that investors might be missing?
A: On a positive note, we believe effective fraud control carries underappreciated upside for large, well-run incumbent providers. While there may be greater uncertainty and more onerous audit and compliance burdens in the near term, the removal of genuine bad actors from the system should tighten provider networks and free up funding for legitimate providers operating in these service categories.
Q: What catalysts or deadlines should stakeholders monitor over the short term?
A: CMS must send a formal Notice of Deferral to Minnesota within 15 days of its February 25th announcement, detailing which payments it has flagged as questionable – this will provide a clearer picture of how the administration is identifying and categorizing fraud. Separately, Minnesota has requested a conformity hearing to plead its case and avoid the threatened funding loss from the noncompliance proceedings, which is a distinct enforcement mechanism from the deferral. If the administration plans to follow through on that threat, the hearing is a prerequisite. We view the Notice of Deferral and the conformity hearing as key indicators for gauging the scope and severity of the administration’s fraud crackdown.
Looking beyond Minnesota, CMS Administrator Mehmet Oz said the agency is planning to take “dramatic and drastic action” against healthcare fraud in California, Massachusetts, and Maine. We are watching to see which other states get caught up in this crackdown and whether providers or payors with geographic concentration are disproportionately exposed.
Q: What is the administration’s actual policy prioritization versus its rhetoric?
A: That is truly the billion-dollar question. If the administration is content with securing headline victories on fraud enforcement in blue states, then the overall impact on Medicaid providers and MCOs will be limited.
Healthcare affordability has emerged as a top concern for voters ahead of a highly competitive 2026 midterm election cycle, and we believe the administration is eager to seize the narrative from Democrats over the One Big Beautiful Bill Act’s (OBBBA’s) Medicaid cuts and the expiration of the Affordable Care Act (ACA) subsidies, both of which will make healthcare more expensive and less accessible. Highlighting fraud, particularly in blue states, is a politically savvy way to reframe the cuts as necessary anti-fraud measures and good governance.
Our base case is that the political incentives favor this approach, with high-profile enforcement actions that generate headlines without fundamentally disrupting Medicaid funding flows. However, if the administration concludes that actual funding withholdings are necessary to maintain credibility on fraud, the calculus shifts meaningfully for providers and MCOs in targeted states.
Read more from Capstone’s healthcare practice:
Cracks in Employer Insurance Create a New Market Opportunity
The Great Coverage Shakeup: Medicare Advantage Stability, The Shrinking of the ACA, and Implications for Healthcare Payors
Provider Pressure: The Looming Headwinds for Medicaid Exposed Providers
